SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Barclays downgrade of Joby to Underweight, citing cash burn and doubts about manufacturing capacity and market share, is driving the selloff and comparisons with upgraded rival Archer. Traders are divided between selling or switching to Archer and viewing the downgrade as a shakeout while maintaining confidence in Jobys technology, Toyota backing, and FAA progress.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase is drawing attention as traders weigh persistent solar-sector pressure from higher borrowing costs and weaker residential demand against its developing IQ SST opportunity for AI data-center power. U.S. production progress and planned demonstrations and customer pilots have fueled rebound and short-squeeze speculation, while skeptics caution that the new business is still unproven and near-term solar headwinds remain.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs pullback is fueling debate over whether buyout hopes have outrun the near-term case for its ulcerative-colitis drug, obefazimod, despite positive Phase 3 data and a planned FDA filing. Bulls see value in the drugs potential and point to Crohns data as a future catalyst, while skeptics say the lack of a deal could leave the shares waiting on clinical and regulatory milestones; some also cite broader biotech weakness.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is drawing attention amid a sharp bank-stock pullback, with traders citing elevated Treasury yields and concern about the upcoming earnings outlook; the CEOs warning of weaker investment-banking fees and roughly flat trading revenue has added to the pressure. Sentiment is split between traders expecting further declines and buyers who see the pullback as an oversold opportunity ahead of results.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Oppenheimers upgrade to Outperform, citing rising contract values and early monetization of agentic-AI traffic, is driving attention to Fastly. Traders are reacting bullishly to the AI-growth thesis, while some question how much that traffic will translate into reported revenue and view upcoming results as a test of the thesis.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is drawing attention around a potential rebound in beaten-down Chinese internet and tech stocks, with traders pointing to bullish options activity, technical support and rotation into China tech. Others remain skeptical, citing the ETFs persistent downtrend, weak market fundamentals and regulatory and geopolitical risks.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention amid a recent pullback, which traders attribute to rising Treasury yields and money rotating back toward tech and growth stocks. The community is split between investors adding shares for long-term dividend income and those questioning the funds appeal versus CDs, cash, or growth-focused ETFs.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off on concerns that SpaceXs planned acquisition of low-band spectrum could help Starlink Mobile compete with established wireless carriers. Traders are split between viewing the threat as a long-term risk to subscribers and pricing and calling the selloff overdone given the time and infrastructure needed to build a competing network, alongside Verizons cash flows and dividend.

Cash Cat

A sharp pullback after a speculative rally is driving discussion, with traders debating whether CASHCAT is a pump-and-dump with weak support or a dip worth buying. Bulls cite its Robinhood-chain presence and claimed launchpad-driven buybacks and burns, while those claims and rumors of exchange or executive support remain unverified.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Rising yields and expectations ahead of Q3 earnings are weighing on bank stocks, with traders concerned about weaker lending and credit quality even as higher rates could support net interest income. Citi discussion is split between investors calling the pullback a buying opportunity and those anticipating cautious results or guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indian companies invest USD 20.5 billion in US, pharma tops

… Embassy & Consulates in India. The pharmaceutical sector accounted for the vast majority … ;s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Granules India Ltd, Jubilant … Group, Lupin Limited, Piramal Pharma Ltd., and Zydus Lifesciences Limited …

Brief India: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums and more

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

Brief India: Primer: Anthem Biosciences (1234D IN) - Apr 2026 and more

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.

Brief India: Amagi Media Labs: Taking Media Companies to the Cloud Universe and more

In this briefing: Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate 1. Amagi Media Labs: Taking Media Companies to the Cloud Universe Amagi's unified cloud-based media infrastructure serves to digitise traditional media content and enable monetisation. Its two-way platform supports not just the content-owners but also distributors globally with varied content access By attracting both media companies and distributors, Amagi benefits from a content-driven flywheel effect, creating structural stickiness with 120+% NRR and 35–50% cost savings for broadcasters. Amagi has been a key enabler for broadcasting for live-events (FIFA, NFL) while its content library attracts small/new OTT platforms.

Brief Multi-Strategy: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective and more

In this briefing: Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Approaches Aimed at Resolving “parent-Subsidiary Listings” in the Broad Sense Remain Effective A common challenge faced by Japanese companies is inability to concentrate resources on businesses with high profit margins and growth potential, resulting in failure to successfully expand promising businesses overseas. Establishing and implementing clear criteria for deciding when to invest in or withdraw from businesses is essential for restructuring the business portfolio. The litmus test is eliminating parent-subsidiary dual listings. The Standard Market is likely to become the main battleground for efforts to resolve parent-subsidiary dual listings.In the Prime Market, increased approaches from activist investors targeting equity-method affiliates are inevitable. 2.

Brief Multi-Strategy: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) and more

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover.

Brief India: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) and more

In this briefing: Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 1. Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Downstream oil products remain elevated, yet oil futures continue to soften. GCC states say that it will take years to rebuild and replace some infrastructure. The petrodollar has taken a hit as Gulf countries are selling less oil and emerging markets are forced to sell dollars to plug deficits caused by higher oil prices. The petroyuan is gaining traction as the Middle East conflict has rerouted some payments through the Chinese CIPS and mBridge networks. 2. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost.

Brief Multi-Strategy: HEW: Rallying into the Void and more

In this briefing: HEW: Rallying into the Void Japan Strategy Weekly Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? 1. HEW: Rallying into the Void No news was good enough news for risk assets to keep rallying, but even a benign end to the US-Iran war will not negate the inflation shock lifting policy rates. EA inflation recovered some of its downside surprise in its final March print, but the UK’s international stature can’t recover. It failed to defend its investing allies. Next week is packed with news for the UK, where the rise in its inflation data is our highlight, with its labour market and global flash PMIs other notable releases. 2. Japan Strategy Weekly Japanese equities posted a modest gain this week, with the Topix Index rising +0.6% and extending its year-to-date advance to +10.3%. The move came against a supportive global backdrop, as U.S. markets rallied strongly— Nasdaq climbed ~4%—helping sustain risk appetite despite pockets of volatility.

Brief Multi-Strategy: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins and more

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins The Stocks to Own in China – Vol. 39 CX Daily: ByteDance’s Billion-Yuan Bet on China’s First AI-Native Hospital? The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Samsung Electronics - Pays Out Special Dividend & Consensus Likely to Raise DPS by 30%+ for 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2.

Brief India: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins and more

In this briefing: Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan The Adani Group Clearance: Deconstructing the CCI Verdict and What It Means for the Conglomerate Primer: Cipla Ltd (CIPLA IN) - Apr 2026 Primer: Indus Towers (INDUSTOW IN) - Apr 2026 1. Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins US Paracetamol prices jumped 24.6% MoM in March 2026 , driven by post-Lunar New Year Chinese supply pullback, Indian facility FDA alerts & surging para-aminophenol cost. Indian API-heavy players like Granules India, Aurobindo, Dr. Reddy's & IPCA face squeeze of input costs & restricted supply of exports , compressing EBITDA when the US pharma tariff threat looms. Integrated giants like Sun Pharma & Cipla have buffers; pure-play API and formulation players like Granules India are most exposed. This situation is worth tracking closely heading into FY26 earnings. 2. Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan Gold loans have overtaken home loans by origination value, reaching ~39% of retail disbursals as of December 2025, with the portfolio growing 4x since March 2022 to ~INR3.38 lakh crore.

Granules India Ltd. engages in the manufacturing and marketing of pharmaceutical products. It operates through the following business segments: Active Pharmaceutical Ingredient, Pharmaceutical Formulation Intermediates, and Finished Dosages. The company was founded by Krishna Prasad Chigurupati on March 18, 1991 and is headquartered in Hyderabad, India.

Feed

News

Sentiment

Fundamentals

Info

GRANULES.NSE Granules India Ltd.

Latest GRANULES.NSE News